U.S. market Closed. Opens in 13 hours 47 minutes

GDTC | CytoMed Therapeutics Limited Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue290.56K270.33K84.18K44.92KN/A
Cost of Revenue77.47K6.48K2.59K3.50KN/A
Gross Profit213.09K263.86K81.59K41.43KN/A
Operating Expenses3.12M1.38M1.28M949.00K451.04K
Selling, General & Admin1.93M443.29K435.31K116.99K29.72K
Research & Development1.20M1.13M806.45K784.20K323.98K
Other Operating ExpensesN/A-195.32K36.13K47.81KN/A
Operating Income-2.91M-1.40M-1.43M-949.00K-446.85K
Other Expenses / Income-219.50K-922.48K-320.96K-513.22K-19.10K
Before Tax Income-3.13M-2.33M-1.53M-1.47M-465.95K
Income Tax Expenses373.001.22K-53.43K84.71KN/A
Net Income-3.13M-2.40M-1.53M-1.47M-465.95K
Interest ExpensesN/A92.99K87.03K79.71KN/A
Basic Shares Outstanding10.63M7.92M6.93M5.90M5.55M
Diluted Shares Outstanding10.63M7.92M6.93M5.90M5.55M
EBITDA-2.94M-1.11M-1.19M-728.02K-349.62K
EBITDA Margin-1,011.10%-410.85%-1,412.07%-1,620.57%0.00%
EBIT-3.13M-2.30M-1.50M-1.30M-465.95K
EBIT Margin-1,077.72%-852.17%-1,782.39%-2,900.03%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙